Skip to main content
    J

    Johnson & Johnson (JNJ)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $253.37
    -0.54 (-0.21%)

    Market Cap: $611.90B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(40/40)
    Avg Surprise
    +4.28%
    Streak
    101 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$3.03
    Range$2.94 - $3.18
    13 analysts
    Revenue Consensus
    $27.3B
    Range$26.9B - $28.2B
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.03---
    Sep 26
    Reported Oct 13
    		$2.59$2.53+2.37%Beat-7.5%
    Jun 26
    Reported Jul 15
    		$2.90$2.84+2.11%Beat+4.7%
    Mar 26
    Reported Apr 14
    		$2.70$2.68+0.75%Beat-2.5%
    Dec 25
    Reported Jan 21
    		$2.46$2.46+0.00%Beat+20.6%
    Sep 25
    Reported Oct 14
    		$2.80$2.76+1.45%Beat+15.7%
    Jun 25
    Reported Jul 16
    		$2.77$2.68+3.36%Beat-1.8%
    Mar 25
    Reported Apr 15
    		$2.77$2.58+7.36%Beat+2.2%
    Dec 24
    Reported Jan 22
    		$2.04$2.01+1.49%Beat-10.9%
    Sep 24
    Reported Oct 15
    		$2.42$2.21+9.50%Beat-9.0%
    Jun 24
    Reported Jul 17
    		$2.82$2.70+4.44%Beat+0.7%
    Mar 24
    Reported Apr 16
    		$2.71$2.65+2.26%Beat+1.1%
    Dec 23
    Reported Jan 23
    		$2.29$2.28+0.44%Beat-2.6%
    Sep 23
    Reported Oct 17
    		$2.66$2.52+5.56%Beat+4.3%
    Jun 23
    Reported Jul 20
    		$2.80$2.62+6.87%Beat+8.1%
    Mar 23
    Reported Apr 18
    		$2.68$2.50+7.20%Beat+0.4%
    Dec 22
    Reported Jan 24
    		$2.35$2.24+4.91%Beat+10.3%
    Sep 22
    Reported Oct 18
    		$2.55$2.49+2.41%Beat-1.9%
    Jun 22
    Reported Jul 19
    		$2.59$2.55+1.57%Beat+4.4%
    Mar 22
    Reported Apr 19
    		$2.67$2.57+3.89%Beat+3.1%
    Dec 21
    Reported Jan 25
    		$2.13$2.12+0.47%Beat+14.5%
    Sep 21
    Reported Oct 19
    		$2.60$2.35+10.64%Beat+18.2%
    Jun 21
    Reported Jul 21
    		$2.48$2.28+8.77%Beat+48.5%
    Mar 21
    Reported Apr 20
    		$2.59$2.35+10.21%Beat+12.6%
    Dec 20
    Reported Jan 26
    		$1.86$1.83+1.64%Beat-1.1%
    Sep 20
    Reported Oct 13
    		$2.20$1.98+11.11%Beat+3.8%
    Jun 20
    Reported Jul 16
    		$1.67$1.51+10.60%Beat-35.3%
    Mar 20
    Reported Apr 14
    		$2.30$2.00+15.00%Beat+9.5%
    Dec 19
    Reported Jan 22
    		$1.88$1.87+0.53%Beat-4.6%
    Sep 19
    Reported Oct 15
    		$2.12$2.01+5.47%Beat+3.4%
    Jun 19
    Reported Jul 16
    		$2.58$2.44+5.74%Beat+22.9%
    Mar 19
    Reported Apr 16
    		$2.10$2.04+2.94%Beat+1.9%
    Dec 18
    Reported Jan 22
    		$1.97$1.95+1.03%Beat+13.2%
    Sep 18
    Reported Oct 16
    		$2.05$2.03+0.99%Beat+7.9%
    Jun 18
    Reported Jul 17
    		$2.10$2.07+1.45%Beat+14.8%
    Mar 18
    Reported Apr 17
    		$2.06$2.00+3.00%Beat+12.6%
    Dec 17
    Reported Jan 23
    		$1.74$1.72+1.16%Beat+10.1%
    Sep 17
    Reported Oct 17
    		$1.90$1.80+5.56%Beat-
    Jun 17
    Reported Jul 18
    		$1.83$1.79+2.23%Beat-
    Mar 17
    Reported Apr 18
    		$1.83$1.77+3.39%Beat-
    Dec 16
    Reported Jan 24
    		$1.58$1.56+1.28%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.12%
    Forward Annual Dividend$5.36
    Payout Ratio46.04%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+4.92%
    5Y CAGR+5.25%
    JNJ dividend history and ex-dividend datesRun JNJ in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio23.79EV/EBITDA19.32x
    Price/FCF27.42xFCF Yield3.65%
    Profitability
    Profit Margin21.50%Operating Margin29.20%
    ROE25.70%ROIC15.76%
    Financial Health
    Debt/Equity0.58xInterest Coverage25.00x
    Current Ratio1.09xQuick Ratio0.81x
    Trading Statistics
    Beta0.21Avg Volume7.63M
    52-Week High$281.0752-Week Low$180.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$255.97
    SMA 20$262.12
    SMA 50$264.93
    SMA 200$242.42
    EMA 10$256.99
    EMA 20$260.12
    EMA 50$261.23
    EMA 200$240.67

    MACD

    Line: -3.37Signal: -2.37Hist: -1.00

    ADX

    ADX: 16.8+DI: 27.1-DI: 32.8

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down92.0
    PSAR$263.63

    Bollinger Bands

    Upper Band$277.11
    Lower Band$247.13
    %B Position1144%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    41.0

    Momentum Oscillators

    Stoch %K23.6
    Stoch %D30.1
    Williams %R-71.3
    ROC (10d)-2.0%
    Momentum-5.29
    CCI (20d)-61.4
    MFI (14d)38.4

    Volatility Measures

    ATR (14d)$6.37(2.5%)
    StdDev (20d)7.49
    Hist Vol27.1%(Moderate)

    Volume Flow

    VWAP$256.14
    OBV257.4M
    AD Line-3.1B
    CMF (20d)-0.089

    Volume Metrics

    Avg Vol (20d)7.8M
    Vol Ratio1.2x
    VWMA (20d)$260.82

    Pivot Points

    R3$261.17
    R2$257.56
    R1$255.73
    Pivot Point$252.12
    S1$250.29
    S2$246.68
    S3$244.85

    Advanced Oscillators

    TSI-17.28
    Ultimate Osc45.6
    KST-40.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$25.31B$24.06B$24.56B$23.99B$23.74B$21.89B$22.52B$22.47B$22.45B$21.38B$21.39B$21.35B
    Cost of Revenue$8.05B$8.11B$7.97B$7.30B$7.63B$7.36B$7.13B$6.96B$6.87B$6.51B$6.80B$6.61B
    Gross Profit$17.26B$15.96B$16.60B$16.69B$16.11B$14.54B$15.39B$15.51B$15.58B$14.87B$14.60B$14.74B
    Operating Expenses$10.12B$9.63B$11.17B$9.66B$9.47B$8.35B$11.81B$10.47B$9.30B$8.96B$10.40B$9.21B
    R&D$3.65B$3.56B$4.33B$3.67B$3.52B$3.23B$5.31B$4.95B$3.63B$3.54B$4.54B$3.65B
    SG&A$6.43B$6.03B$6.75B$5.92B$5.89B$5.11B$6.45B$5.48B$5.68B$5.26B$5.81B$5.40B
    Operating Income$7.14B$6.33B$5.43B$7.03B$6.65B$6.18B$3.58B$5.04B$6.28B$5.91B$4.19B$5.53B
    Interest Income$219.00M$229.00M$237.00M$227.00M$260.00M$332.00M$281.00M$292.00M$395.00M$364.00M$363.00M$374.00M
    Interest Expense$281.00M$272.00M$214.00M$245.00M$308.00M$204.00M$137.00M$193.00M$270.00M$155.00M$151.00M$192.00M
    Income Before Tax$6.75B$5.99B$4.97B$7.49B$6.49B$13.63B$3.89B$3.34B$5.75B$3.71B$4.83B$5.22B
    Income Tax Expense$1.21B$755.00M$-150,000,000$2.34B$954.00M$2.63B$456.00M$644.00M$1.06B$459.00M$694.00M$908.00M
    Net Income$5.53B$5.24B$5.12B$5.15B$5.54B$11.00B$3.43B$2.69B$4.69B$3.25B$4.05B$26.03B
    EBITDA$8.77B$8.04B$6.95B$9.29B$8.48B$15.28B$5.64B$5.08B$7.41B$5.32B$6.46B$6.86B
    EBIT$6.81B$6.03B$4.94B$7.51B$6.54B$13.50B$3.74B$3.24B$5.62B$3.50B$4.61B$5.04B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Diversification Test Every Investor Should Run (Built Into GNG)

    Counting holdings is misleading - a 12-stock, 10-industry model that appeared diversified lost most diversification once positions were grouped by underlying return drivers Academic rules conflict on count - Evans & Archer (1968) says 10-15 stocks, Statman (1987) 30-40, Statman (2004) >300...

    Leo Nelissen
    •
    6/29/26
    •
    376
    Portfolio Construction
    Also mentions:
    DHRTMOODFLINTUUNP

    Abbott: The Market Priced the Dent and Forgot the Cargo

    Market punished Abbott - stock down ~34% from 52-week high $139.06 to ~$91, yet TTM revenue $45.1B, gross margin 56.4%, operating cash flow $9.46B and free cash flow $7.38B ($4.22/sh, 4.85% FCF yield) Closed oncology acquisition for ~$21B equity (~$23B incl assumed debt), funded with $20B notes...

    Glenn Ford
    •
    6/9/26
    •
    255
    Dividend Kings, medical-technology, value investing
    Also mentions:
    MDTJNJ

    The Intelligent Compounder's Playbook: Five Dividend Aristocrats Built to Outlast the Next Downturn

    Five dividend aristocrats stress-tested across 170+ quality metrics, ranked by conviction GNG Safety Scores span from 70.47 to a perfect 100 across the final five picks One insurer just posted record combined ratios and landed a $20B government contract The "cheapest" candidate on the screen carried...

    Glenn Ford
    •
    3/18/26
    •
    393
    dividend aristocrats
    Also mentions:
    JNJPGPEPSJMABBV

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined...

    Glenn Ford
    •
    2/24/26
    •
    139
    Healthcare Stocks, healthcare-innovation
    Also mentions:
    TMDXREGNJNJ

    The Toll Booth on Biotech’s Highway: Why Halozyme’s Royalty Engine Could Make Patient Investors Rich

    Halozyme's ENHANZE platform is a toll booth on injectable biologics: partners develop drugs, HALO collects royalties on every dose sold across 10 commercialized products in 100+ global markets. Three major deals in 100 days: Elektrofi acquisition ($750M+ in Oct), Skye Bioscience (Jan 5)...

    Glenn Ford
    •
    1/14/26
    •
    188
    Biotech, value investing, Healthcare Stocks
    Also mentions:
    TAKJNJ

    Government Contracts

    Gov Obligations (TTM)
    $22685
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26126N0271Department of Veterans AffairsDepartment of Veterans Affairs$22685Jan 2, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Sep 30, 2026.

    News

    Billionaire Patrick Soon-Shiong wins wider FDA approval for bladder cancer drug

    Billionaire Patrick Soon-Shiong's ImmunityBio Inc. received expanded FDA approval for its bladder cancer drug Anktiva...

    Billionaires.Africa•10/16/26•Neutral

    Should Strong Q3 Revenue Require Action From Ecolab (ECL) Investors?

    Ecolab (ECL) is projected to exceed Q3 revenue consensus, driven by organic growth and value-based pricing, with management expected to maintain 2026 adjusted EPS guidance. The company's investment narrative is...

    Simply Wall Street•10/16/26•Neutral

    Lilly, Pfizer, J&J among winners of EU drug recommendations this month

    An expert panel of the EU drug regulator has recommended six new medicines and five label expansions for approval in October 2026. This marks significant regulatory wins for companies like Eli Lilly, Pfizer...

    Seeking Alpha•10/16/26•Bullish

    Protagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks Research

    Zacks Research has upgraded Protagonist Therapeutics (NASDAQ:PTGX) to a "strong buy" rating, joining other analysts who maintain a bullish outlook with a consensus "buy" rating and an average price target of $154.44....

    MarketBeat•10/16/26•Neutral

    ETFs Are Net Sellers of Revvity (RVTY) on Wednesday

    ETFs were net sellers of Revvity (RVTY) shares for the second consecutive day on Wednesday, October 14, with a net outflow of $25.7 million. Although more ETFs bought shares than sold...

    Yahoo Finance•10/16/26•Somewhat-Bullish

    JNJ Valuation and Fair Value

    P/E
    23.8x
    Forward P/E
    21.0x
    EV/EBITDA
    19.3x
    P/FCF
    27.4x
    PEG
    2.8x
    P/B
    7.2x
    See GNG's fair value

    JNJ Profitability: Margins, ROIC and FCF

    Gross margin
    67.9%
    Operating margin
    29.2%
    Net margin
    21.5%
    ROIC
    15.8%
    ROE
    25.7%
    FCF margin
    22.7%
    FCF yield
    3.6%

    JNJ Competitors

    CompanyTicker
    Eli Lilly and CompanyLLY
    AbbVie IncABBV
    Merck & Company IncMRK
    UnitedHealth Group IncorporatedUNH
    Novartis AG ADRNVS
    AstraZeneca PLCAZN
    Thermo Fisher Scientific IncTMO
    Amgen IncAMGN

    Sector: Healthcare

    JNJ Analyst Ratings

    Consensus
    Buy
    Analysts
    23
    Strong Buy
    5
    Buy
    11
    Hold
    6
    Sell
    1
    Strong Sell
    0

    JNJ Bull Case vs Bear Case

    Bull case

    • JNJ earns a 15.8% return on invested capital.
    • JNJ converts 22.7% of revenue into free cash flow.
    • JNJ has a 21.5% net profit margin.

    JNJ Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    2.4%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $3.03

    JNJ Dividend

    Forward yield
    2.1%
    Payout ratio
    46.0%
    3Y DPS growth
    4.9%
    5Y DPS growth
    5.2%
    Pay months
    Mar, Jun, Sep, Dec
    JNJ dividend history

    Frequently Asked Questions About JNJ

    What is JNJ's current dividend yield?

    Johnson & Johnson (JNJ) has a forward dividend yield of 2.12%.

    Does JNJ pay dividends?

    Yes, Johnson & Johnson pays dividends with a forward dividend yield of 2.12%.

    What is JNJ's P/E ratio?

    Johnson & Johnson has a price-to-earnings (P/E) ratio of 23.79.

    What is JNJ's market cap?

    Johnson & Johnson (JNJ) has a market capitalization of $611.90B with a current stock price of $253.37.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In